USPH · Investment summary · as of 4 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
The business does not meet the quality standard for its economic type.
At $77.85, USPH requires a 1% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 14%.
Declared MARGIN rather than growth.
The conditions that would settle the disagreement are dated 3 years from the memo date (4 August 2026 to 4 August 2029) -- THE same HORIZON AS THE LOSS OPERAND, per the 4 August 2026 rule requiring horizons on both operands.
The value rests on an exit multiple of 23.5x, a terminal operating margin of 10% and a 8.0% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: The CY2027 or CY2028 Medicare Physician Fee Schedule returns to cuts and USPH cannot offset it a sixth time.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Declared MARGIN rather than growth. |
| What do we forecast? | Revenue growth of 14% demonstrated; a terminal operating margin of 10%; an exit multiple of 23.5x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On terminal margin, the difference between what the price requires and what the business has demonstrated is +0.3 percentage points. |
| What is it worth? | Twelve-month target $82.00, +5% from the struck price. Scenario-weighted expected return net of costs +5.3%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| tested each quarter from Q2 2026 | Mature-clinic (same-store) revenue growth, PT segment, 10-Q Segment… | Neither leg of the condition opposite is met at this date | below +1.0% for two consecutive quarters |
| tested each quarter from Q2 2026 | Consolidated operating margin, TTM | At or above 9.0% for two consecutive quarters | below 9.0% for two consecutive quarters |
| CMS final rule, approximately November 2026 | CY2027 Medicare Physician Fee Schedule conversion factor, CMS final… | Neither leg of the condition opposite is met at this date | a cut of 1.5% or more |
| tested each quarter | Redeemable NCI carrying amount against attributable net income, both… | Redeemable NCI grows more than 15% year-on-year while attributable net income grows at least 5% | redeemable NCI grows more than 15% year-on-year while attributable net income grows less than 5% |
The CY2027 or CY2028 Medicare Physician Fee Schedule returns to cuts and USPH cannot offset it a sixth time.
Estimated probability 30%, against the 25% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
Trim or exit on valuation and opportunity cost when the forward 12-month expected return falls below the hurdle after costs, or when the traded NTM EV/EBIT multiple re-rates above the 1-year average of 16.88x without a corresponding improvement in mature-clinic growth above +4%. On approach to the $82.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not met | Is the business worth owning under its declared economic type? |
| Valuation | Not determined | Is the operating path required by today's price achievable? Not established on the evidence on file. |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | The CY2027 or CY2028 Medicare Physician Fee Schedule returns to cuts and USPH cannot offset it a sixth time. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +0.3 percentage points more growth than the price requires. The most important unresolved uncertainty is whether the operating path today's price requires is achievable; the evidence does not settle it. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $68.51, which forces an immediate review.